Global Herpes Simplex Virus (HSV) Testing Market, By Type (Antibody/Antigen Based Kit, Viral Culture Test Kits, Nucleic Acid Amplification-Based Kits, Other), End-User (Diagnostic Centers, Hospitals, Home Use, Other), Application (Research Use, Clinical Diagnostics), Indication (HSV-1, HSV-2, HSV-1/HSV-2) – Industry Trends and Forecast to 2029
Market Analysis and Size
Herpes simplex virus (HSV) testing analyzers have been increasingly popular in recent decades as a result of major technological breakthroughs and expanding healthcare business demands. Herpes simplex virus (HSV) testing focuses on the examination of internal body fluids and provides precise diagnostic information. Modern herpes simplex virus (HSV) testing is built on the foundation of traditional manual laboratory tests. However, as technology has progressed, testing methods have developed, and various tests may now be performed in automated laboratories utilizing complex devices such as chemical analyzers.
Data Bridge Market Research analyses that the herpes simplex virus (HSV) testing market which was USD 2.32 billion in 2021, would rocket up to USD 2.96 billion by 2029, and is expected to undergo a CAGR of 3.10% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Antibody/Antigen Based Kit, Viral Culture Test Kits, Nucleic Acid Amplification-Based Kits, Other), End-User (Diagnostic Centers, Hospitals, Home Use, Other), Application (Research Use, Clinical Diagnostics), Indication (HSV-1, HSV-2, HSV-1/HSV-2)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbott (U.S.), Abcam plc. (U.K.), bioMérieux (France), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), DiaSorin S.p.A. (Italy), Quidel Corporation (U.S.), Luminex Corporation (U.S.), Merck KGaA (Germany), QIAGEN (Germany), Norgen Biotek Corp. (Canada), Hologic Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Meridian Bioscience, Inc. (U.S.), Teco Diagnostics (U.S.), GSK plc. (U.K.), Agenus Inc. (U.S.), Maruho Co., Ltd. (Japan), and Sanofi (France)
|
|
Market Opportunities
|
|
Market Definition
The contagious herpes simplex virus (HSV) can spread through saliva, sperm, and vaginal secretions, resulting in painful blisters or ulcers. Blood testing, fluid collection, and physical examinations are typically used to diagnose it. Currently, the best available treatments for patients are antiviral drugs like famciclovir, acyclovir, and valacyclovir. These drugs can be taken orally or intravenously (IV) to help with symptom relief, lessen the frequency and intensity of outbreaks, and stop the virus from spreading.
Herpes Simplex Virus (HSV) Testing Market Dynamics
Drivers
- Rising number of patients with the herpes simplex virus
In the forecast period of 2022–2029, factors such as the rate of new infections, the expansion of clinical research, and technological advancements are projected to boost the growth of the herpes simplex virus (HSV) testing market. However, the development of accurate screening tests and the expansion of the healthcare industry will create additional growth prospects for the herpes simplex virus (HSV) testing market throughout the forecast period.
- Rising prevalence of chronic disorders
HSV can cause serious side effects like encephalitis and keratitis in those with long-term or chronic conditions and increase the chance of contracting and transmitting the HIV infection. This is one of the key factors influencing the need for HSV therapy around the world. Moreover, when an infant is exposed to HSV in the vaginal tract during birth, neonatal herpes, a dangerous illness, may develop. The market is benefiting from the increased birth rate because neonatal herpes can result in long-term neurologic impairment or baby death.
- Increased prevalence of hospital-acquired infections
Herpes simplex virus treatment demand is primarily driven by the increased prevalence of hospital-acquired infections and low immunity disorders due to the abrupt global spread of the COVID-19 pandemic. Furthermore, HSV can cause serious difficulties in people with long-term or chronic illnesses, such as keratitis and encephalitis, increasing the risk of transmission and acquisition of the human immunodeficiency virus (HIV) disease further driving the market's expansion.
Opportunities
The market is expanding as a result of increased research and development activity. Due to the significant financial burden that herpes simplex virus infections place on healthcare systems worldwide, there is a high potential for growth in the market for herpes simplex virus treatments. Over the forecast period, this market is anticipated to grow at a faster rate than average.
Restraints/Challenges
Limited availability of laboratories along with lack of skilled personnel are acting as market restraints for the growth of the herpes simplex virus (HSV) testing in the above mentioned forecast period. However, one of the main barriers to the market's expansion is the social stigma attached to sexually transmitted illnesses, compounded by increased product recalls.
This herpes simplex virus (HSV) testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the herpes simplex virus (HSV) testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Herpes Simplex Virus (HSV) Testing Market
The COVID-19 pandemic had a major effect on market expansion. The researcher established the link between the herpes simplex virus and the SARS-CoV-2 virus in numerous studies, which positively affected the market by increasing demand for antiviral medications for treatment. The COVID-19 and its effects on those with the herpes simplex virus are also predicted to fuel market growth (HSV). The odds ratio for the prevalence of the herpes simplex virus type-1 in the COVID-19 group was 5.27, while it was 2.81 percent in the hospital population. As a result, the ongoing epidemic increased demand for herpes simplex virus treatments. However, the COVID-19 pandemic disrupted the development of various treatments and medications for illnesses other than COVID-19 and had an influence on global pharmaceutical supply chains and treatment protocols, which in turn had an impact on the market for treating herpes simplex virus.
Recent Development
- In October 2021, United BioPharma collaborated with the Shanghai Public Health Clinical Centre and the Department of Microbiology and Immunology at Cheng Kung University to study the efficacy of UB-621, a best-in-class long-acting medication for genital herpes caused by simplex viruses 1 and 2. (HSV 1 and HSV2).
- In July 2021, AiCuris Anti-infective Cures AG began Phase III development of pritelivir, a novel helicase-primase inhibitor, for acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients.
Global Herpes Simplex Virus (HSV) Testing Market Scope
The herpes simplex virus (HSV) testing market is segmented on the basis of type, application, indication and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Antibody/Antigen Based Kit
- Viral Culture Test Kits
- Nucleic Acid Amplification-Based Kits
- Other
End-User
- Diagnostic Centers
- Hospitals
- Home Use
- Other
Application
- Research Use
- Clinical Diagnostics
Indication
- HSV-1
- HSV-2
- HSV-1/HSV-2
Herpes Simplex Virus (HSV) Testing Market Regional Analysis/Insights
The herpes simplex virus (HSV) testing market is analysed and market size insights and trends are provided by country, type, application, indication and end-user as referenced above.
The countries covered in the herpes simplex virus (HSV) testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the herpes simplex virus (HSV) testing market due to the rising number of clinical research and improved healthcare infrastructure prevalence.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the increasing health awareness among the people and rising demand of advanced medical technology.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Herpes Simplex Virus (HSV) Testing Market Share Analysis
The herpes simplex virus (HSV) testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to herpes simplex virus (HSV) testing market.
Some of the major players operating in the herpes simplex virus (HSV) testing market are:
- Abbott (U.S.)
- Abcam plc. (U.K.)
- bioMérieux (France)
- Thermo Fisher Scientific, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- DiaSorin S.p.A. (Italy)
- Quidel Corporation (U.S.)
- Luminex Corporation (U.S.)
- Merck KGaA (Germany)
- QIAGEN (Germany)
- Norgen Biotek Corp. (Canada)
- Hologic Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Meridian Bioscience, Inc. (U.S.)
- Teco Diagnostics (U.S.)
- GSK plc. (U.K.)
- Agenus Inc. (U.S.)
- Maruho Co., Ltd. (Japan)
- Sanofi (France)
SKU-